FDA approves Abilify drug to treat acute manic and mixed episodes in children

Abilify, developed by Otsuka jointly with Bristol-Myers Squibb, was approved by the Food and Drug Administration (FDA) for treatment of acute manic and mixed episodes in children aged 10-17 associated with bipolar disorder.

	FDA approves Abilify drug to treat acute manic and mixed episodes in children

The FDA has given the approval on the basis of four-week-study results. The drug showed effectiveness compared to a placebo.

The drug was first approved on November 15, 2002 for the treatment of schizophrenia, the sixth atypical antipsychotic medication of its kind in adults.

Read more news